All Stories

  1. A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial)

    Article • Leukemia & Lymphoma, June 2019, Taylor & Francis

    prof Won Seog Kim

  2. Recent advances in understanding and managing T-cell lymphoma

    Article • F1000Research, December 2017, Faculty of 1000, Ltd.

    prof Won Seog Kim

  3. Report of the 6th International Workshop on PET in lymphoma

    Article • Leukemia & Lymphoma, March 2017, Taylor & Francis

    prof Won Seog Kim, Egesta Lopci, Prof. Emanuele Zucca

  4. frontline treatment of DLBCL

    Article • F1000Research, August 2016, Faculty of 1000, Ltd.

    prof Won Seog Kim

  5. Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia

    Article • OncoTargets and Therapy, September 2014, Taylor & Francis

    prof Won Seog Kim